Cosmo Pharmaceuticals N.V.
SIX: COPN.SW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Swiss Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Giovanni Di Napoli
- Employees
- 321
- Headquarters
- Dublin, Ireland
- IPO year
- 2007
- Market cap
- CHF 1.2B
- Website
- https://www.cosmopharma.com
Loading COPN…
Loading profile data…Frequently asked questions about COPN
What does Cosmo Pharmaceuticals N.V. (COPN.SW) do?
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses a...
Where does COPN.SW trade?
Cosmo Pharmaceuticals N.V. (COPN.SW) trades on the Swiss Exchange.
What sector is COPN.SW in?
Cosmo Pharmaceuticals N.V. (COPN.SW) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Cosmo Pharmaceuticals N.V.?
Giovanni Di Napoli is the chief executive officer of Cosmo Pharmaceuticals N.V. (COPN.SW).
Where is Cosmo Pharmaceuticals N.V. headquartered?
Cosmo Pharmaceuticals N.V. is headquartered in Ireland.
Does COPN.SW pay a dividend?
Yes — Cosmo Pharmaceuticals N.V. (COPN.SW) paid a trailing twelve-month dividend of CHF 3.17 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did COPN.SW go public?
Cosmo Pharmaceuticals N.V. (COPN.SW) completed its initial public offering in 2007.